跳至主要内容
临床试验/NCT06013514
NCT06013514招募中不适用

A Prospective, Multi-center, Observational, Non Comparative, Post-marketing Surveillance Study to Obtain Clinical Outcome Data on the Nagor PERLE Range of Silicone Breast Implants When Used in Breast Implantation

GCA (Eurosilicone)2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
2
主要终点
Rate of implant rupture

研究概览

简要总结

Patients can undergo breast implant surgery for multiple reasons; cosmetic and reconstructive being the primary indications. In order to confidently state safety and due to strict regulation on medical devices it is important to maintain a record of safety and performance with all medical implants.

This study is designed to collect data on a new generation of smooth mammary implants to assess the long term performance and safety data on this type of gel-filled mammary breast implant.

The two main complications of breast implants are capsular contracture and rupture; these complications can take years to develop. The study is designed to evaluate the occurrence of these two primary complication as well as other secondary complications over a period of 10 years. Patient follow up will be carried out pre-operatively and post operatively at 12 months and then 3, 5, 8 and 10 years thereafter.

The study will be carried out over 10 years to adequately assess complications which may only occur over the lifetime of the device such as systemic complications

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Genetic female subjects aged ≥18 and ≤65
  • Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:-
  • i) Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs of animal origin (bovine, porcine)). ii) Primary breast augmentation (cosmetic surgery) with or without mastopexy iii) Breast revision surgery with or without mastopexy c) Subjects who have received a Nagor PERLE implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow up appointments as per the study protocol.

排除标准

  • Subjects undergoing implant augmentation with a BMI > 30 and undergoing reconstruction with a BMI >
  • Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.
  • Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer related clinical studies.
  • Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.
  • Subjects who have ADMs of synthetic origin.
  • Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.
  • Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.
  • Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.
  • Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.
  • Subjects with a known history of compromised wound healing.
  • Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
  • Women who are pregnant and/or current breast feeders who do not stop breast feeding within 3 months of getting breast implants
  • Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant

研究组 & 干预措施

Smooth Silicone Breast Implant

干预措施: PERLE Sterile Smooth Opaque gel filled mammary implants (Device)

结局指标

主要结局

Rate of implant rupture

时间窗: 10 years post-surgery

Rate of capsular contracture (Baker grade III-IV)

时间窗: 10 years post-surgery

次要结局

  • rate and frequency of any adverse events(10 years post-surgery)
  • Patient satisfaction(10 years post-surgery)
  • Rate of the secondary surgical procedures required for correction of complications(10 years post-surgery)
  • Rate and frequency of local complications associated with the use of Nagor gel-filled mammary implants(10 years post-surgery)

研究者

发起方
GCA (Eurosilicone)
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Post-market Prospective Clinical Study of Nagor... | 临床试验